News & Research
New studies, trials, regulatory changes and news about the compounds on Amino Reference. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-05.
- The Week Progress Got More Specific
Vastkind
A briefing on the TRIUMPH-2 diabetes trial of retatrutide (GLP3-R) separates an 18.8% treatment-regimen weight-loss figure from a 20.8% efficacy estimate. It also notes a planned United States filing in early 2027, which is a regulatory step and not an approval.
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Communications in Mass Spectrometry
A mass-spectrometry study reports how retatrutide, the compound this site lists as GLP3-R, can be detected in human plasma and urine and describes its excretion profile. The findings matter for sports-drug testing because they show the compound can be identified in biological samples.
- EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
J Hepatol
European liver, diabetes, and obesity societies issued guidance on using semaglutide as MASH-targeted therapy. The GLP1-S page should treat MASH as a human-guidance use and cite this, rather than leaving liver benefit at a lower grade.
- Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.
Nat Med
Nature Medicine published a randomized placebo-controlled trial of semaglutide in type 2 diabetes with kidney disease. This is primary human evidence and should set the kidney-benefit grade on the GLP1-S page.
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clin Obes
A systematic review pooled head-to-head studies of tirzepatide versus semaglutide for weight loss. Comparative wording on the GLP2-T and GLP1-S pages should follow this human evidence rather than cross-trial claims.
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Lancet
Lancet published the phase 3 ACHIEVE-4 trial of cardiovascular safety for oral orforglipron versus insulin glargine in type 2 diabetes at higher cardiovascular risk. This is the primary citation for any heart-safety statement on the orforglipron page.
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
N Engl J Med
The New England Journal of Medicine published a trial of once-weekly survodutide in adults with obesity and type 2 diabetes. That paper should be the lead human citation for efficacy and safety on the survodutide page.
- Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
Pharmacy Times
Phase 3 TRIUMPH-2, published in The Lancet, found retatrutide, sold in research channels as GLP3-R, cut weight by up to 18.8% at 80 weeks in type 2 diabetes, with more hypotension and dysesthesia. Lilly is aiming at an FDA filing in early 2027, which is not an approval.
- Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
ScienceAlert
The NEJM TRIUMPH-1 trial reported about 25% weight loss at 80 weeks on retatrutide 12 mg in obesity without diabetes, and nearly 30% in a smaller two-year extension. That non-diabetes result should be stated separately from the type 2 diabetes trial on the GLP3-R page.
- New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
MedPage Today
ACHIEVE-4 found orforglipron noninferior to insulin glargine for MACE-4, 4.2% versus 5.0%, hazard ratio 0.84, but it was not powered to prove a cardiovascular benefit. The orforglipron page should call this a heart-safety comparison, not evidence that the pill prevents cardiovascular events.
- CagriSema Curbs 'Food Noise,' Organ Fat in Patients With Obesity, T2D Respectively
Pharmacy Times
EASD abstracts reported that cagrilintide plus semaglutide changed brain responses to high-calorie food cues and reduced liver and pancreas fat. An FDA weight-management decision is expected in the fourth quarter of 2026, so the pages should record that timeline without treating conference abstracts as a full regrade.
- EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
Pharmacy Times
The same phase 2b of eloralintide plus tirzepatide cut HbA1c by up to 2.9% in adults with obesity and type 2 diabetes. Adverse-event discontinuations were 10.8% to 27% when both drugs were escalated together, which is the tolerability figure to show if the combination is mentioned.
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (recruiting)
ClinicalTrials.gov
A trial is recruiting children and adolescents with excess body weight to test cagrilintide and CagriSema. The site should say these products are not established for minors and that this is a pharmaceutical trial, not a reason to use research material in children.
- Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.
BMJ Open
A EudraVigilance analysis examined tirzepatide reports tied to suboptimal outcomes and drug-use problems. The GLP2-T safety section should add any disproportionate real-world signals this paper actually identifies.
- Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.
Hum Psychopharmacol
A 12-month real-world cohort tracked renal biomarkers and lithium safety after tirzepatide was started in people with bipolar disorder already on lithium. The GLP2-T safety section should cover this interaction setting and follow the signal the paper actually found.
- Orforglipron Noninferior to Insulin Glargine for Cardiovascular Outcomes in T2D
Medscape
The same ACHIEVE-4 readout found better A1c and weight than insulin glargine, while gastrointestinal events drove discontinuation in 15.4% versus 5.4%. Those tolerability figures belong in the orforglipron safety section beside the cardiovascular result.
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Clin Obes
A systematic review and meta-analysis assessed depression burden and risk in people receiving semaglutide. The GLP1-S psychiatric safety text should be aligned to the pooled result instead of left as anecdote.
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis (recruiting)
ClinicalTrials.gov
The LIVERAGE trial of survodutide in MASH with moderate or advanced fibrosis is recruiting. Readers should see this as ongoing human research, not as evidence that survodutide treats liver fibrosis.
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (recruiting)
ClinicalTrials.gov
A companion LIVERAGE trial of survodutide in MASH with cirrhosis is recruiting. The page should separate this higher-risk ongoing study from any claim of benefit in advanced liver disease.
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) (completed)
ClinicalTrials.gov
The survodutide cardiovascular outcomes trial, SYNCHRONIZE-CVOT, is listed as completed. This registry update does not include results, so no cardiovascular benefit or harm should be claimed from the status change alone.
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC
Eloralintide, a selective amylin agonist not in the catalogue, plus tirzepatide produced up to 23.3% weight loss at 48 weeks in obesity with type 2 diabetes, and Lilly plans phase 3 by year-end. The site should flag the new peptide and should not paste the combination result onto tirzepatide monotherapy.
- Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging.
Aging Cell
A study reports that elamipretide rejuvenated oocyte quality and restored female fertility during reproductive aging. The listing does not state the model, so the SS-31 page should not add a human fertility benefit until that is confirmed.
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Diabetes Obes Metab
A paper reports nephroprotective effects of survodutide in hypertension-accelerated diabetic kidney disease. Confirm whether it is human or animal before it is allowed to change the kidney grade on the survodutide page.
- Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Contemp Clin Trials
A review covers the mechanism, clinical evidence, and open questions for survodutide in obesity. It is a check on what the page should still call uncertain, not a new trial result.
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (not yet recruiting)
ClinicalTrials.gov
SYNCHRONIZE-START, a survodutide weight-loss trial in people with overweight or obesity without diabetes, is listed as not yet recruiting. The page should not describe that non-diabetes phase 3 study as enrolled or completed.
- Semaglutide Demonstrates Benefits Across Frailty Levels.
JAMA
JAMA reported that semaglutide showed benefits across frailty levels. If the GLP1-S page implies benefit is limited to healthier adults, this human report should be checked before that limitation is kept.
- Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
BMJ
BMJ reported phase 3 retatrutide results suggesting weight loss of up to 25%. Use it as a journal pointer for GLP3-R, and prefer the primary trial paper for dose, duration, and population.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Diabetes Care
This paper estimates tirzepatide MACE benefit in SURPASS-CVOT by imputing a placebo from REWIND, rather than reporting a new outcome trial. The site should not present that estimate as direct evidence of cardiovascular benefit.
- Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.
JACC Case Rep
A case report describes hemodynamic compromise linked to semaglutide-associated abdominal distension. This is a rare safety signal and should be listed as a single case, not as an expected effect.
- Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
Pharmacy Times
A Lilly-funded cross-trial model, not a head-to-head study, linked orforglipron 17.2 mg to about 1.5% more weight loss and 0.3% more A1C reduction than oral semaglutide 25 mg. The site should not upgrade comparative claims from this indirect sponsored analysis.